The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
HOME > ORGANIZATION
ORGANIZATION
- Self-Medication and Proper Drug Pricing 2 Sides of the Same Coin: Professor
November 8, 2024
- Japan Wholesaler Group to Continue Stressing Plight of Supply Disruption
October 25, 2024
- Drug Therapy for Fetal Tachyarrhythmia Gets 1st Health Coverage in Japan
October 21, 2024
- Off-Year Price Revision Has Accomplished Mission: JPMA Exec
October 18, 2024
- JaDHA Inks MOU with DTA to Collaborate in DTx Push
October 16, 2024
- JaDHA Creates Hypothetical Case Collection to Push Two-Stage Approval of SaMD
October 11, 2024
- EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
- EFPIA Japan Chair Urges All Players to Join Forces in Drug Loss Fight
October 10, 2024
- New Administration Must Not Stop Efforts toward Bolstering Pharma Industry: JPMA Chief
October 9, 2024
- Pharma Labor Group Renews Call for Abolition of Off-year Revisions
October 9, 2024
- Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
- Japan Generic Use Rate Reaches 83.5% in April-June: JGA
September 30, 2024
- Japan Wholesalers Enjoy Growth as COVID Meds Enter Commercial Route
September 27, 2024
- Keidanren Calls for Review of Japan's Unique Pharmaceutical Regulations
September 19, 2024
- Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
September 12, 2024
- Japan’s Generic Use Rate at 82.7% in FY2023: JGA
August 1, 2024
- FPMAJ Renews Call to Ensure Stable Supply System to Prep for COVID Outbreak
July 25, 2024
- Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
- Off-Year Scheme Drifting Away from Four-Minister Deal: JPMA Exec
July 19, 2024
- Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
July 19, 2024
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…